Dermata Therapeutics, Inc. is a San Diego-based dermatology company that has transitioned from a development-stage pharmaceutical firm into a direct-to-consumer skincare business. The company is building its commercial strategy around the Tome brand and its proprietary Bioneedle technology, a hero ingredient derived from 100% freshwater sponge that is wild-harvested and minimally processed into a fine, purified powder.
Dermata launched its first product, Tome Foundational Treatment, in August 2026 as a once-weekly skin-renewal treatment. It is advancing a second product, Tome Clearing Treatment, an over-the-counter acne treatment combining salicylic acid with Bioneedle. Investors follow DRMA for its early commercialization progress, its transition to recurring subscription revenue, and its ability to scale a differentiated brand in the competitive premium skincare market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the 30 days ended mid-November, DRMA declined approximately 36%, falling from a closing price of about $0.80 in late October to roughly $0.51. The move was punctuated by elevated volume and steady selling pressure rather than a single-day collapse.
The quarterly picture is steeper. After a sharp run-up in August that carried shares to a peak near $1.72, the stock has retreated roughly 63% over the past three months. The downtrend reflects a fading of the mid-August speculative surge and the re-emergence of balance-sheet and dilution concerns as the dominant themes for this micro-cap name.
Several verified factors shaped the recent decline. On October 9, Dermata filed a registration statement covering the resale of up to 6.92 million shares by selling stockholders, a disclosure that reinforced concerns about potential supply overhang and dilution in a thinly traded, low-float stock.
Cash-runway risk also remained in focus. In its first-quarter filing, Dermata disclosed $6.9 million in cash and cash equivalents as of March 31, 2026, an accumulated deficit, and substantial doubt about its ability to continue as a going concern absent additional financing. While the company has since begun generating product revenue, its commercial operations are still early-stage.
The pullback also followed a period of unusually heavy trading. A burst of speculative activity in mid-October, including a single session with tens of millions of shares traded, gave way to a sustained decline as momentum faded. Positive operational news, including cosmetic study results and the start of an acne-treatment trial, was not enough to offset the financing-driven pressure on sentiment.
The broader multi-month trend reflects a sharp reversal from August's speculative spike. Dermata's August 25 launch of Tome Foundational Treatment, priced at $178 for a four-treatment set, briefly energized the stock and lifted shares toward their peak. However, the rally was not sustained as attention shifted back to fundamentals.
Dermata's Q3 2026 results, reported November 10, confirmed the company's transition to a revenue-generating commercial skincare business and noted that roughly 30% of orders arrived through subscriptions. Yet the company remains pre-profitability, with modest initial revenue and ongoing marketing spend. The combination of limited float, recurring financing needs, and a still-uncertain path to scale has kept the stock under pressure throughout the quarter.
Looking ahead, investors should monitor Dermata's subscription growth and revenue trajectory for Tome Foundational Treatment, as well as progress on Tome Clearing Treatment, which the company expects to launch in the first half of 2027. Cash position and any new financing, equity, or warrant activity will remain central given the going-concern disclosures.
Consumer adoption, marketing efficiency, and competitive positioning in the premium skincare category are also key variables. Because DRMA is a low-float micro-cap, trading volumes and liquidity can amplify price movements. These are informational factors to track, not a basis for any specific investment decision.
In my own work, I regularly review automated strategies through Tickeron’s AI Trading Bots to see how different approaches are performing on names like this. The platform lets users explore a range of data-driven signals and backtested scenarios that complement fundamental research, helping to put price action and volume patterns into broader context without replacing individual analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DRMA saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In 91 of the 98 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for DRMA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 53 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DRMA entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where DRMA advanced for three days, in 148 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
DRMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.085) is normal, around the industry mean (3.596). P/E Ratio (-0.182) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. DRMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology